Publications by authors named "Gerald Downey"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

21

Total Likes

153

Extended Reach

5,823,260

Social Features

55
H
Hematologic Cancer after Gene Therapy for Cerebral Adrenoleukodystrophy.
Christine N Duncan, Jacob R Bledsoe, Bartosz Grzywacz, Amy Beckman, Melissa Bonner, Gerald F Downey

N Engl J Med· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lentiviral haematopoietic stem-cell gene therapy for early-onset metachromatic leukodystrophy: long-term results from a non-randomised, open-label, phase 1/2 trial and expanded access.
Francesca Fumagalli, Valeria Calbi, Maria Grazia Natali Sora, Maria Sessa, Cristina Baldoli, Gerald F Downey

Lancet· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.
Robert H I Andtbacka, Frances Collichio, Kevin J Harrington, Mark R Middleton, Gerald Downey

J Immunother Cancer· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.
Peter Mohr, Sebastian Haferkamp, Andreas Pinter, Carsten Weishaupt, Margit A Huber, Gerald Downey

Adv Ther· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Malignancy in Giant Cell Tumor of Bone: A Review of the Literature.
Emanuela Palmerini, Piero Picci, Peter Reichardt, Gerald Downey

Technol Cancer Res Treat· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical clinical guide on the use of talimogene laherparepvec monotherapy in patients with unresectable melanoma in Europe.
Ralf Gutzmer, Kevin J Harrington, Christoph Hoeller, Celeste Lebbé, Josep Malvehy, Gerald Downey

Eur J Dermatol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review of methods for comparing treatments evaluated in studies that form disconnected networks of evidence.
John W Stevens, Christine Fletcher, Gerald Downey, Anthea Sutton

Res Synth Methods· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Jason Chesney, Sanjay Awasthi, Brendan Curti, Laura Hutchins, Gerald Linette, Gerald F Downey

Melanoma Res· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
J Han van Krieken, George Kafatos, James Bennett, Laurent Mineur, Jiří Tomášek, Gerald Downey

BMC Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in patients with stage IIIB/C and IVM1a melanoma: subanalysis of the Phase III OPTiM trial.
Kevin J Harrington, Robert Hi Andtbacka, Frances Collichio, Gerald Downey, Lisa Chen

Onco Targets Ther· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.
Jörg Trojan, Laurent Mineur, Jiří Tomášek, Etienne Rouleau, Pavel Fabian, Gerald Downey

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Literature review of visual representation of the results of benefit-risk assessments of medicinal products.
Christine E Hallgreen, Shahrul Mt-Isa, Alfons Lieftucht, Lawrence D Phillips, Diana Hughes, Gerald Downey

Pharmacoepidemiol Drug Saf· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations for benefit-risk assessment methodologies and visual representations.
Diana Hughes, Ed Waddingham, Shahrul Mt-Isa, Alesia Goginsky, Edmond Chan, Gerald F Downey

Pharmacoepidemiol Drug Saf· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of acute liver injury associated with use of antibiotics. Comparative cohort and nested case-control studies using two primary care databases in Europe.
Ruth Brauer, Ian Douglas, Luis Alberto Garcia Rodriguez, Gerald Downey, Consuelo Huerta

Pharmacoepidemiol Drug Saf· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit-risk assessment in a post-market setting: a case study integrating real-life experience into benefit-risk methodology.
Christine E Hallgreen, Hendrika A van den Ham, Shahrul Mt-Isa, Simon Ashworth, Richard Hermann, Gerald Downey

Pharmacoepidemiol Drug Saf· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.
Ann C Collier, Camlin Tierney, Gerald F Downey, Susan H Eshleman, Angela Kashuba

HIV Clin Trials· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
Constance A Benson, Florin Vaida, Diane V Havlir, Gerald F Downey, Michael M Lederman

J Infect Dis· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.
Angela Dm Kashuba, Camlin Tierney, Gerald F Downey, Edward P Acosta, Emanuel N Vergis

AIDS· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DEET mosquito repellent provides personal protection against malaria: a household randomized trial in an Afghan refugee camp in Pakistan.
Mark Rowland, Gerald Downey, Abdur Rab, Tim Freeman, Nasir Mohammad

Trop Med Int Health· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DEET mosquito repellent sold through social marketing provides personal protection against malaria in an area of all-night mosquito biting and partial coverage of insecticide-treated nets: a case-control study of effectiveness.
Mark Rowland, Tim Freeman, Gerald Downey, Abdul Hadi, Mohammed Saeed

Trop Med Int Health· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of cutpoints for phenotypic hypersusceptibility to efavirenz.
Ronald J Bosch, Gerald F Downey, David A Katzenstein, Nicholas Hellmann, Lee Bacheler

AIDS· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis